Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size, Share and Growth Outlook, 2026

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Gastrointestinal Stromal Tumor (GIST) Therapeutics Market size is forecast to increase from $896.51 Million in 2026 to $1634.95 Million in 2034 at a CAGR of 7.8% between 2026 and 2034.

The Gastrointestinal Stromal Tumor (GIST) Therapeutics market report provides detailed analysis and outlook of Gastrointestinal Stromal Tumor (GIST) Therapeutics segments including By Product Type (Marketed Drugs, Pipeline Drugs), By Drug Category (Tyrosine Kinase Inhibitors, Targeted Antibodies, Chemotherapy, Immunotherapy), By Route of Administration (Oral, Intravenous), By End-User (Hospitals & Oncology Clinics, Specialty Cancer Centers, Ambulatory Care Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry Overview

Dual KIT Inhibition and Combination Targeted Therapies Advancing GIST Treatment Outcomes

The Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry is advancing rapidly through precision oncology approaches targeting KIT-driven oncogenic pathways. Cogent Biosciences, Inc. has achieved FDA acceptance of its New Drug Application (NDA) with Priority Review for bezuclastinib in combination with sunitinib for patients with advanced GIST who have progressed after imatinib therapy. The program, supported by Breakthrough Therapy Designation and the Real-Time Oncology Review (RTOR) pathway, reflects accelerated regulatory evaluation for high-need oncology indications. Clinical evidence from the Phase 3 PEAK trial demonstrated that dual KIT inhibition significantly reduced the risk of disease progression or death compared to sunitinib monotherapy, highlighting the growing importance of combination tyrosine kinase inhibition strategies in overcoming resistance in heterogeneous tumor populations.

Clinical Trial Evidence Supporting Progression-Free Survival Improvements in Resistant GIST

The Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry is increasingly defined by robust clinical trial programs evaluating next-generation tyrosine kinase inhibitors in resistant disease settings. The Phase 3 PEAK trial, presented at major oncology congresses, reported a median progression-free survival of 16.5 months for bezuclastinib plus sunitinib compared to 9.2 months for standard therapy, along with improved objective response rates. These outcomes underscore the clinical benefit of dual-targeted inhibition in managing advanced GIST characterized by complex mutations in KIT exons 9, 11, and 17. Ongoing multi-center trials evaluating sequential TKI strategies, including ripretinib-based regimens, further reinforce the shift toward mutation-adaptive treatment frameworks designed to address tumor heterogeneity and resistance evolution.

Next-Generation Tyrosine Kinase Inhibitor Sequencing Strategies in Advanced GIST Management

The Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry is witnessing a transition toward optimized sequencing of targeted therapies to extend disease control in advanced settings. Investigational programs led by Deciphera Pharmaceuticals and Zai Lab are evaluating switch-control tyrosine kinase inhibitors in post-frontline progression scenarios. These studies aim to determine the most effective treatment sequences for maintaining long-term progression-free survival in patients with multi-exon KIT mutations. This evolving therapeutic paradigm emphasizes precision sequencing strategies, integrating molecular profiling with tailored drug selection to maximize response durability in refractory GIST populations.

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Gastrointestinal Stromal Tumor (GIST) Therapeutics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Novartis AG, Pfizer Inc., Bayer AG, Blueprint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Ariad Pharmaceuticals, Inc. (Takeda). The Gastrointestinal Stromal Tumor (GIST) Therapeutics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Gastrointestinal Stromal Tumor (GIST) Therapeutics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Gastrointestinal Stromal Tumor (GIST) Therapeutics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Gastrointestinal Stromal Tumor (GIST) Therapeutics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Gastrointestinal Stromal Tumor (GIST) Therapeutics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Competitive Benchmarking and Company Analysis

Leading companies in Gastrointestinal Stromal Tumor (GIST) Therapeutics industry include- Novartis AG, Pfizer Inc., Bayer AG, Blueprint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Ariad Pharmaceuticals, Inc. (Takeda). The Gastrointestinal Stromal Tumor (GIST) Therapeutics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Gastrointestinal Stromal Tumor (GIST) Therapeutics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Gastrointestinal Stromal Tumor (GIST) Therapeutics market remains one of the strongest-performing segments in the country.
The US Gastrointestinal Stromal Tumor (GIST) Therapeutics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Gastrointestinal Stromal Tumor (GIST) Therapeutics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Gastrointestinal Stromal Tumor (GIST) Therapeutics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Gastrointestinal Stromal Tumor (GIST) Therapeutics markets

Canada's strong Gastrointestinal Stromal Tumor (GIST) Therapeutics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Gastrointestinal Stromal Tumor (GIST) Therapeutics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Gastrointestinal Stromal Tumor (GIST) Therapeutics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Gastrointestinal Stromal Tumor (GIST) Therapeutics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Gastrointestinal Stromal Tumor (GIST) Therapeutics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Gastrointestinal Stromal Tumor (GIST) Therapeutics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Gastrointestinal Stromal Tumor (GIST) Therapeutics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Gastrointestinal Stromal Tumor (GIST) Therapeutics sales through 2034

France Gastrointestinal Stromal Tumor (GIST) Therapeutics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Gastrointestinal Stromal Tumor (GIST) Therapeutics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Gastrointestinal Stromal Tumor (GIST) Therapeutics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Gastrointestinal Stromal Tumor (GIST) Therapeutics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Gastrointestinal Stromal Tumor (GIST) Therapeutics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Gastrointestinal Stromal Tumor (GIST) Therapeutics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Gastrointestinal Stromal Tumor (GIST) Therapeutics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Segmentation

By Product Type
Marketed Drugs
Pipeline Drugs
By Drug Category
Tyrosine Kinase Inhibitors
Targeted Antibodies
Chemotherapy
Immunotherapy
By Route of Administration
Oral
Intravenous
By End-User
Hospitals & Oncology Clinics
Specialty Cancer Centers
Ambulatory Care Centers

Top Companies in Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry

Novartis AG
Pfizer Inc.
Bayer AG
Blueprint Medicines Corporation
Deciphera Pharmaceuticals, Inc.
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
Sun Pharmaceutical Industries Ltd.
Ariad Pharmaceuticals, Inc. (Takeda)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025